论文部分内容阅读
目的整合素α_2β_1为整合素家族的一员,近来的研究发现整合素在肿瘤的转移发展中有重要的作用。本文通过对骨肉瘤肺转移患者血浆中整合素α_2β_1表达的研究,探讨其与肺转移发生的相关性及临床意义。方法选取肺转移的骨肉瘤16例,未转移的骨肉瘤20例,普通体检者32例,采集血样离心处理后取血浆,用ELISA法检测整合素α_2β_1。结果正常体检者(1.85±0.39)μg/L,骨肉瘤未转移者(2.06±0.41)μg/L,骨肉瘤肺转移者(3.15±0.80)μg/L。结论实验结果表明骨肉瘤肺转移患者血中整合素α_2β_1表达水平较正常人和未转移骨肉瘤患者是明显升高的。这对于高度恶性的骨肉瘤的诊断及骨肉瘤患者的预后的判定可能有帮助,整合素α_2β_1作为药物治疗的靶分子的可能,及其对抗物能否起到抑制骨肉瘤转移传播有待于进一步研究。
Purpose Integrin α_2β_1 is a member of the integrin family. Recent studies have found that integrins play an important role in tumor metastasis. In this paper, the expression of integrin α_2β_1 in the plasma of patients with lung metastasis of osteosarcoma and its correlation with lung metastasis and its clinical significance. Methods Sixteen osteosarcoma lung metastases, 20 non - metastatic osteosarcoma and 32 normal controls were collected. Plasma samples were collected after centrifugation and the integrin α_2β_1 was detected by ELISA. Results The average score of normal controls (1.85 ± 0.39) μg / L, no metastasis of osteosarcoma (2.06 ± 0.41) μg / L, and the metastasis of osteosarcoma (3.15 ± 0.80) μg / L were found. Conclusion The experimental results show that the expression of integrin α_2β_1 in patients with osteosarcoma lung metastasis is significantly higher than that in normal and non-metastatic osteosarcoma patients. This may be helpful for the diagnosis of highly malignant osteosarcoma and the prognosis of patients with osteosarcoma. The possibility of using integrinα_2β_1 as a target for drug therapy and whether its antagonist can inhibit osteosarcoma metastasis remains to be further studied .